Greenwich GLSI 深 沪
等待开盘 05-19 09:30:00 美东时间
26.88
-0.330
-1.21%
华盛通- 最 高28.00
- 今 开27.21
- 成交量 8.23万股
- 最 低 26.60
- 昨 收 27.21
- 总市值 3.72亿
- 52周最高 34.10
- 市盈率 静 --
- 换手率 0.59%
- 52周最低 7.78
- 委 比 98.02%
- 总股本 1385.45万
- 历史最高 158.07
- 量 比 0.45
- 振 幅 5.15%
- 历史最低 3.262
- 每 手 1
- 风险率 7.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial results for miv-cel. Other gainers include HCAI, ELPW, and ALP.
04-22 17:31
Greenwich LifeSciences Reports 70%–80% Drop In Cancer Recurrence In Early Trial Data
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an
04-20 18:10
Greenwich LifeSciences Says Breast Cancer Therapy Could Double Patient Reach With New Patent Claims
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an
04-07 18:04
Greenwich LifeSciences says new patent claims could double GLSI-100 market to 88,000 patients/year
Greenwich LifeSciences says new patent claims could double GLSI-100 market to 88,000 patients/year Greenwich Lifesciences disclosed new patent claims tied to already presented open-label data from Phase III FLAMINGO-01 for GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences. Cla
04-07 18:03
BUZZ-U.S. STOCKS ON THE MOVE-Rivian, Biohaven, CervoMed
BUZZ-U.S. STOCKS ON THE MOVE-Rivian, Biohaven, CervoMed Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 19 (Reuters) - Wall Street's main indexes were set to open lower on
03-19 21:15
BUZZ-Greenwich LifeSciences rises after expanding late‑stage breast cancer trial
BUZZ-Greenwich LifeSciences rises after expanding late‑stage breast cancer trial ** Shares of biotech firm Greenwich LifeSciences GLSI.O rise about 1.1% to $27 premarket ** Co says it has expanded its late‑stage trial of GLSI‑100, an experimental treatment aimed at preventing breast cancer recurrenc
03-19 18:50
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting
Greenwich LifeSciences, Inc. announced updates on its Phase III clinical trial, FLAMINGO-01, evaluating GLSI-100, an immunotherapy for preventing breast cancer recurrences. Two abstracts and posters were accepted for presentation at the AACR Annual Meeting 2026, focusing on immune response data and trial design. GLSI-100 has shown a 70-80% reduction in recurrence rates in early analysis. The trial, led by prominent oncologists and researchers, is...
03-18 10:00
BUZZ-U.S. STOCKS ON THE MOVE-Uber, Honeywell, Delta
BUZZ-U.S. STOCKS ON THE MOVE-Uber, Honeywell, Delta Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 17 (Reuters) - U.S. stock index futures slipped on Tuesday as the Middle
03-17 19:42
